ALX ONCOLOGY HOLDINGS INC
Moat Score — ALX Oncology Holdings Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | ALX Oncology holds patents on evorpacept's specific fusion-protein engineering, which is designed to avoid the anemia-inducing Fc-effector activity seen in rival CD47 antibodies, giving it real differentiated intellectual property within a scientifically contested target class. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage biotech, ALX Oncology has no manufacturing or cost-scale advantage and would need to build or contract commercial-scale production only after regulatory approval, which has not yet occurred. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, ALX Oncology has no current pricing power; any future oncology drug pricing would be negotiated against payers and compared to existing immuno-oncology treatment costs. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in a biologic drug development business; value is determined by clinical trial data and regulatory approval, not by usage or user scale. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once oncologists adopt a treatment regimen, some prescribing inertia and combination-protocol familiarity develops, but with no approved product yet, ALX Oncology cannot currently claim any real switching-cost advantage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The immuno-oncology combination therapy market is large and can support multiple approved agents targeting different mechanisms, so ALX Oncology gains little protection from efficient-scale dynamics against both CD47-class rivals and unrelated combination-therapy competitors. |